These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 6450726)

  • 1. A low molecular weight inhibitor of the alternative complement pathway. I. Its isolation from human urine and the reaction mechanism.
    Nagaki K; Matsumoto M; Kitamura H
    Immunology; 1980 Dec; 41(4):789-98. PubMed ID: 6450726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of alternative complement pathway components with human blood platelets: secretion and localization of factor D and beta 1H Globulin.
    Kenney DM; Davis AE
    Clin Immunol Immunopathol; 1981 Dec; 21(3):351-63. PubMed ID: 6459901
    [No Abstract]   [Full Text] [Related]  

  • 3. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).
    Seya T; Okada M; Matsumoto M; Hong KS; Kinoshita T; Atkinson JP
    Mol Immunol; 1991 Oct; 28(10):1137-47. PubMed ID: 1833639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
    Waldo FB; Forristal J; Beischel L; West CD
    J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
    Fearon DT
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The separation of functionally distinct forms of the third component of human complement (C3).
    Parkes C; DiScipio RG; Kerr MA; Prohaska R
    Biochem J; 1981 Mar; 193(3):963-70. PubMed ID: 6458280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation of bovine complement factor H.
    Mhatre A; Aston WP
    Vet Immunol Immunopathol; 1987 Apr; 14(4):357-75. PubMed ID: 2955562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement 1 inhibitor is a regulator of the alternative complement pathway.
    Jiang H; Wagner E; Zhang H; Frank MM
    J Exp Med; 2001 Dec; 194(11):1609-16. PubMed ID: 11733575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement.
    Pangburn MK; Müller-Eberhard HJ
    J Exp Med; 1980 Oct; 152(4):1102-14. PubMed ID: 6903192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b.
    Kazatchkine MD; Fearon DT; Silbert JE; Austen KF
    J Exp Med; 1979 Nov; 150(5):1202-15. PubMed ID: 501288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the alternative complement pathway.
    Fearon DT
    CRC Crit Rev Immunol; 1979 Nov; 1(1):1-32. PubMed ID: 162484
    [No Abstract]   [Full Text] [Related]  

  • 12. The quest for an intrinsic C3 activating factor in human glomerular disease.
    Roberts JL; Lewis EJ
    Surv Immunol Res; 1982; 1(2):191-8. PubMed ID: 6227068
    [No Abstract]   [Full Text] [Related]  

  • 13. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).
    Seya T; Holers VM; Atkinson JP
    J Immunol; 1985 Oct; 135(4):2661-7. PubMed ID: 3161944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The alternative pathway of complement.
    Pangburn MK; Müller-Eberhard HJ
    Springer Semin Immunopathol; 1984; 7(2-3):163-92. PubMed ID: 6238433
    [No Abstract]   [Full Text] [Related]  

  • 15. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
    Sahu A; Isaacs SN; Soulika AM; Lambris JD
    J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
    Fishelson Z; Müller-Eberhard HJ
    J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-surface regulation of the human alternative pathway of complement. Sheep but not rabbit erythrocytes express factor I-dependent cofactor activity.
    Ezzell JL; Parker CJ
    Scand J Immunol; 1992 Jul; 36(1):79-87. PubMed ID: 1535452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alternative complement pathway].
    Jouvin MH; Kazatchkine M
    Sem Hop; 1984 May; 60(19):1371-8. PubMed ID: 6326330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The alternative complement pathway].
    Jouvin MH; Kazatchkine M
    Pathol Biol (Paris); 1983 Dec; 31(10):839-46. PubMed ID: 6230588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.